-DOCSTART- -X- O
The -X- _ O
rapid -X- _ O
emergence -X- _ O
and -X- _ O
subsequent -X- _ O
spread -X- _ O
of -X- _ O
the -X- _ O
novel -X- _ O
2009 -X- _ O
Influenza -X- _ O
A -X- _ O
/ -X- _ O
H1N1 -X- _ O
virus -X- _ O
( -X- _ O
2009 -X- _ O
H1N1 -X- _ O
) -X- _ O
has -X- _ O
prompted -X- _ O
the -X- _ O
World -X- _ O
Health -X- _ O
Organization -X- _ O
to -X- _ O
declare -X- _ O
the -X- _ O
first -X- _ O
pandemic -X- _ O
of -X- _ O
the -X- _ O
21 -X- _ O
( -X- _ O
st -X- _ O
) -X- _ O
century -X- _ O
, -X- _ O
highlighting -X- _ O
the -X- _ O
threat -X- _ O
of -X- _ O
influenza -X- _ O
to -X- _ O
public -X- _ O
health -X- _ O
and -X- _ O
healthcare -X- _ O
systems. -X- _ O
Widespread -X- _ O
resistance -X- _ O
to -X- _ O
both -X- _ O
classes -X- _ O
of -X- _ O
influenza -X- _ O
antivirals -X- _ O
( -X- _ O
adamantanes -X- _ O
and -X- _ O
neuraminidase -X- _ O
inhibitors -X- _ O
) -X- _ O
occurs -X- _ O
in -X- _ O
both -X- _ O
pandemic -X- _ O
and -X- _ O
seasonal -X- _ O
viruses -X- _ O
, -X- _ O
rendering -X- _ O
these -X- _ O
drugs -X- _ O
to -X- _ O
be -X- _ O
of -X- _ O
marginal -X- _ O
utility -X- _ O
in -X- _ O
the -X- _ O
treatment -X- _ O
modality. -X- _ O
Worldwide -X- _ O
, -X- _ O
virtually -X- _ O
all -X- _ O
2009 -X- _ O
H1N1 -X- _ O
and -X- _ O
seasonal -X- _ O
H3N2 -X- _ O
strains -X- _ O
are -X- _ O
resistant -X- _ O
to -X- _ O
the -X- _ O
adamantanes -X- _ O
( -X- _ O
rimantadine -X- _ O
and -X- _ O
amantadine -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
majority -X- _ O
of -X- _ O
seasonal -X- _ O
H1N1 -X- _ O
strains -X- _ O
are -X- _ O
resistant -X- _ O
to -X- _ O
oseltamivir -X- _ O
, -X- _ O
the -X- _ O
most -X- _ O
widely -X- _ O
prescribed -X- _ O
neuraminidase -X- _ O
inhibitor -X- _ O
( -X- _ O
NAI -X- _ O
) -X- _ O
. -X- _ O
To -X- _ O
address -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
more -X- _ O
effective -X- _ O
therapy -X- _ O
, -X- _ O
we -X- _ O
evaluated -X- _ O
the -X- _ O
in -X- _ O
vitro -X- _ O
activity -X- _ O
of -X- _ O
a -X- _ O
triple -X- _ B-Intervention
combination -X- _ I-Intervention
antiviral -X- _ I-Intervention
drug -X- _ I-Intervention
( -X- _ I-Intervention
TCAD -X- _ I-Intervention
) -X- _ I-Intervention
regimen -X- _ I-Intervention
composed -X- _ O
of -X- _ O
drugs -X- _ O
with -X- _ O
different -X- _ O
mechanisms -X- _ O
of -X- _ O
action -X- _ O
against -X- _ O
drug-resistant -X- _ O
seasonal -X- _ O
and -X- _ O
2009 -X- _ O
H1N1 -X- _ O
influenza -X- _ O
viruses. -X- _ O
Amantadine -X- _ B-Intervention
, -X- _ I-Intervention
ribavirin -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
oseltamivir -X- _ I-Intervention
, -X- _ I-Intervention
alone -X- _ I-Intervention
and -X- _ I-Intervention
in -X- _ I-Intervention
combination -X- _ I-Intervention
, -X- _ O
were -X- _ O
tested -X- _ O
against -X- _ O
amantadine- -X- _ B-Patient
and -X- _ I-Patient
oseltamivir- -X- _ I-Patient
resistant -X- _ I-Patient
influenza -X- _ I-Patient
A -X- _ I-Patient
viruses -X- _ I-Patient
using -X- _ O
an -X- _ O
in -X- _ O
vitro -X- _ O
infection -X- _ O
model -X- _ O
in -X- _ O
MDCK -X- _ O
cells. -X- _ O
Our -X- _ O
data -X- _ O
show -X- _ O
that -X- _ O
the -X- _ O
triple -X- _ B-Outcome
combination -X- _ I-Outcome
was -X- _ I-Outcome
highly -X- _ I-Outcome
synergistic -X- _ I-Outcome
against -X- _ I-Outcome
drug-resistant -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
synergy -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
triple -X- _ I-Outcome
combination -X- _ I-Outcome
was -X- _ I-Outcome
significantly -X- _ I-Outcome
greater -X- _ I-Outcome
than -X- _ I-Outcome
the -X- _ I-Outcome
synergy -X- _ I-Outcome
of -X- _ I-Outcome
any -X- _ I-Outcome
double -X- _ I-Outcome
combination -X- _ I-Outcome
tested -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
the -X- _ I-Outcome
combination -X- _ I-Outcome
of -X- _ I-Outcome
two -X- _ I-Outcome
NAIs. -X- _ I-Outcome
Surprisingly -X- _ O
, -X- _ O
amantadine -X- _ O
and -X- _ O
oseltamivir -X- _ O
contributed -X- _ O
to -X- _ O
the -X- _ O
antiviral -X- _ O
activity -X- _ O
of -X- _ O
the -X- _ O
TCAD -X- _ B-Outcome
regimen -X- _ I-Outcome
against -X- _ I-Outcome
amantadine- -X- _ I-Outcome
and -X- _ I-Outcome
oseltamivir- -X- _ I-Outcome
resistant -X- _ I-Outcome
viruses -X- _ I-Outcome
, -X- _ O
respectively -X- _ O
, -X- _ O
at -X- _ O
concentrations -X- _ O
where -X- _ O
they -X- _ O
had -X- _ O
no -X- _ O
activity -X- _ O
as -X- _ O
single -X- _ O
agents -X- _ O
, -X- _ O
and -X- _ O
at -X- _ O
concentrations -X- _ O
that -X- _ O
were -X- _ O
clinically -X- _ O
achievable. -X- _ O
Our -X- _ O
data -X- _ O
demonstrate -X- _ O
that -X- _ O
the -X- _ O
TCAD -X- _ O
regimen -X- _ O
composed -X- _ O
of -X- _ O
amantadine -X- _ O
, -X- _ O
ribavirin -X- _ O
, -X- _ O
and -X- _ O
oseltamivir -X- _ O
is -X- _ O
highly -X- _ O
synergistic -X- _ O
against -X- _ O
resistant -X- _ O
viruses -X- _ O
, -X- _ O
including -X- _ O
2009 -X- _ O
H1N1. -X- _ O
The -X- _ O
TCAD -X- _ B-Outcome
regimen -X- _ I-Outcome
overcomes -X- _ I-Outcome
baseline -X- _ I-Outcome
drug -X- _ I-Outcome
resistance -X- _ I-Outcome
to -X- _ I-Outcome
both -X- _ I-Outcome
classes -X- _ I-Outcome
of -X- _ I-Outcome
approved -X- _ I-Outcome
influenza -X- _ I-Outcome
antivirals -X- _ I-Outcome
, -X- _ O
and -X- _ O
thus -X- _ O
may -X- _ O
represent -X- _ O
a -X- _ O
highly -X- _ O
active -X- _ O
antiviral -X- _ O
therapy -X- _ O
for -X- _ O
seasonal -X- _ O
and -X- _ O
pandemic -X- _ O
influenza -X- _ O
. -X- _ O

